Deferred registration: Quotient Sciences Code: QSC303849
| ISRCTN | ISRCTN19554893 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN19554893 |
| Integrated Research Application System (IRAS) | 1013719 |
| Sponsor | Neurocrine Switzerland GmbH |
| Funder | Neurocrine Switzerland GmbH |
- Submission date
- 18/08/2026
- Registration date
- 18/08/2026
- Last edited
- 18/08/2026
- Recruitment status
- Recruiting
- Overall study status
- Deferred
- Condition category
- Other
Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Contact information
Principal investigator
Mere Way, Ruddington Fields, Ruddington
Nottingham
NG11 6JS
United Kingdom
| Phone | +44 (0)3303031000 |
|---|---|
| recruitment@weneedyou.co.uk |
Public, Scientific
Switzerland Innovation Park Basel Area AG
Hegenheimermattweg 167A
Allschwil
4123
Switzerland
| Phone | +359 887580697 |
|---|---|
| Centermedinfo@neurocrine.com |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Non-randomized controlled trial |
| Masking | Open (masking not used) |
| Control | Active |
| Assignment | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Purpose | Phase I trial in healthy volunteers |
| Scientific title | Deferred registration: Quotient Sciences Code: QSC303849 [Full scientific title to be added on or before the deferral expiry date] |
| Study objectives | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Ethics approval(s) |
Submitted 19/06/2026, London Brent Research Ethics Committee (REC) (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)2071048128; brent.rec@hra.nhs.uk), ref: 26/LO/0239 |
| Health condition(s) or problem(s) studied | Healthy volunteers |
| Intervention | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 06/02/2027 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 55 Years |
| Sex | All |
| Target sample size at registration | 16 |
| Key inclusion criteria | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Key exclusion criteria | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Date of first enrolment | 19/08/2026 |
| Date of final enrolment | 06/02/2027 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Ruddington Fields
Ruddington
Nottingham
NG11 6JS
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
18/08/2026: Study's existence confirmed by the MHRA.